Loading…
Edwards Lifesciences Corporation is projected to rise to $102.82 by 2027, a +19% move from its current price of $86.51. EW is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $85.21 | $86.54 | $87.89 | +0.03% |
| May 30 | $84.69 | $86.57 | $88.49 | +0.07% |
| May 31 | $84.30 | $86.60 | $88.96 | +0.10% |
| Jun 1 | $83.98 | $86.63 | $89.36 | +0.14% |
| Jun 2 | $83.70 | $86.66 | $89.72 | +0.17% |
| Jun 3 | $83.45 | $86.69 | $90.05 | +0.21% |
| Jun 4 | $83.23 | $86.72 | $90.35 | +0.24% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $83.23 | $86.72 | $90.35 | +0.24% |
| Week 2 | $82.02 | $86.93 | $92.12 | +0.48% |
| Week 3 | $81.15 | $87.13 | $93.55 | +0.72% |
| Week 4 | $80.46 | $87.34 | $94.82 | +0.96% |
| Week 5 | $79.87 | $87.55 | $95.97 | +1.20% |
| Week 6 | $79.37 | $87.76 | $97.05 | +1.45% |
| Week 7 | $78.92 | $87.97 | $98.06 | +1.69% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL and EVOQUE brands.
The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS brand name; INSPIRIS RESILIA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILILIA, a pre-assembled tissue valve conduit for complex combined procedures; and MITRIS RESILIA valve. It distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
Edwards Lifesciences Corporation (EW) is a healthcare stock with a current price of $85.72 and a market cap of $49.36B. It is ranked 324 among listed stocks. The stock sits in a bullish technical context, supported by key moving averages and a defined price range.
The current price and market position reflect a company with a sizable market presence and a defined technical setup. The stock trades with a bullish tilt in the near term, as indicated by indicators such as RSI and moving averages, and a clear 30-day price range.
Forecasts project a long-term upward trajectory, with the 2026 average price at $85.72 and substantial growth through 2050, culminating in a 2050 average price of $733.34 and a maximum forecast of $1,202.15.
A major floor 15.2% below — a decisive break under it would weaken the trend.
The nearest floor, 10.8% below — buyers have tended to step in here.
Price is pressing into resistance (1.2% away) — a breakout level to watch.
A major ceiling 8.8% above — clearing it would confirm fresh momentum.
Key EW support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of EW market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $85.20 | Buy | $85.44 | Buy |
| MA 10 | $83.47 | Buy | $84.13 | Buy |
| MA 20 | $82.62 | Buy | $83.03 | Buy |
| MA 50 | $81.63 | Buy | $82.24 | Buy |
| MA 100 | $82.11 | Buy | $81.99 | Buy |
| MA 200 | $81.42 | Buy | $80.98 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 62.46 | Neutral |
| Stoch RSI (14) | 85.91 | Sell |
| CCI (20) | 153.88 | Buy |
| Williams %R (14) | -9.93 | Info |
| MACD (12,26,9) | 0.62 | Buy |
| ROC (12) | 8.19 | Buy |
| Bollinger %B (20,2) | 0.92 | Neutral |
| Stochastic %K (14) | 90.07 | Sell |
| TRIX (15) | 0.08 | Buy |
| Awesome (5,34) | 3.54 | Buy |
| Ultimate (7,14,28) | 73.22 | Sell |
| Momentum (10) | 6.78 | Buy |
| Aroon Osc (25) | 40.00 | Buy |
| Hull MA (9) | 87.27 | Sell |
| ADX (14) | 12.82 | Neutral |
| ATR (14) | 1.19 | Info |
The sentiment is BULLISH, with RSI14 at 60 and price action supported by the SMA50 at $81.46 and SMA200 at $81.33. The stock is trading around the major moving averages and remains above a near-term support of $77.17 while facing resistance at $85.78.
Over the next 30 days, the price range is expected to be between $77.27 and $95.10, indicating potential upside while remaining within a defined band. The current setup suggests a constructive near-term bias, with room to test the resistance level around $85.78 as the range unfolds.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $75.87 | $86.51 | $113.11 | 0% | Neutral | |
| $83.99 | $102.82 | $131.74 | +19% | Neutral | |
| $87.01 | $108.45 | $142.59 | +25% | Bullish | |
| $94.63 | $119.74 | $160.70 | +38% | Bullish | |
| $109.55 | $140.47 | $191.86 | +62% | Bullish | |
| $127.65 | $165.65 | $229.78 | +91% | Bullish | |
| $141.11 | $185.17 | $260.47 | +114% | Bullish | |
| $148.26 | $196.59 | $280.07 | +127% | Bullish | |
| $159.11 | $213.06 | $307.13 | +146% | Bullish | |
| $164.80 | $222.75 | $324.65 | +157% | Bullish | |
| $250.46 | $353.03 | $539.04 | +308% | Bullish | |
| $460.13 | $695.45 | $1,137.94 | +704% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $75.87 | $86.51 | $101.10 | +0.00% |
| June 2026 | $74.84 | $87.30 | $103.82 | +0.92% |
| July 2026 | $76.07 | $89.25 | $107.14 | +2.23% |
| August 2026 | $75.36 | $88.82 | $107.40 | -0.48% |
| September 2026 | $74.88 | $88.58 | $107.75 | -0.27% |
| October 2026 | $76.79 | $91.14 | $111.46 | +2.89% |
| November 2026 | $77.87 | $92.70 | $113.90 | +1.71% |
| December 2026 | $76.76 | $91.65 | $113.11 | -1.14% |
Click any year to see its month-by-month EW forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Edwards Lifesciences Corporation's 2026 outlook centres on $86.51, within a $75.87 to $113.11 range. That marks a 0% change versus current levels. A consolidation phase looks the most probable path here.
By 2027, EW could reach as high as $131.74, with a base case around $102.82 and support toward $83.99 — roughly +19% from $86.51. Price action looks broadly range-bound.
Expect EW to range from $87.01 to $142.59 through 2028. The $108.45 average target implies a +25% move from current prices. That is up +5% on the projected 2027 average. Buyers look set to stay in control over this stretch.
The EW price prediction for 2029 points to an average of $119.74 (low $94.63, high $160.70) — a potential gain of +38% on today's $86.51. Momentum favours further upside here.
In 2030, EW is projected to trade between $109.55 and $191.86, averaging $140.47 — a potential gain of +62% from today's $86.51. That is up +17% on the projected 2029 average. Buyers look set to stay in control over this stretch.
Edwards Lifesciences Corporation's 2031 outlook centres on $165.65, within a $127.65 to $229.78 range. That is up +18% on the projected 2030 average. That marks a +91% change versus current levels. Momentum favours further upside here.
By 2032, EW could reach as high as $260.47, with a base case around $185.17 and support toward $141.11 — roughly +114% from $86.51. Buyers look set to stay in control over this stretch.
Expect EW to range from $148.26 to $280.07 through 2033. The $196.59 average target implies a +127% move from current prices. That is up +6% on the projected 2032 average. Momentum favours further upside here.
The EW price prediction for 2034 points to an average of $213.06 (low $159.11, high $307.13) — a potential gain of +146% on today's $86.51. Buyers look set to stay in control over this stretch.
In 2035, EW is projected to trade between $164.80 and $324.65, averaging $222.75 — a potential gain of +157% from today's $86.51. That is up +5% on the projected 2034 average. Momentum favours further upside here.
Edwards Lifesciences Corporation's 2040 outlook centres on $353.03, within a $250.46 to $539.04 range. That is up +58% on the projected 2035 average. That marks a +308% change versus current levels. Buyers look set to stay in control over this stretch.
By 2050, EW could reach as high as $1,137.94, with a base case around $695.45 and support toward $460.13 — roughly +704% from $86.51. Momentum favours further upside here.
Investing $1,000 in EW today (≈ 11.559357 EW) could be worth
$8,038.93
+$7,038.93 (+704%) by 2050 · US Dollar
Based on the average projected EW price of $695.45 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in EWwould be worth at today's price.
$1,000 invested in EW on May 27, 2025 (≈ 13.119916 EW) would be worth
$1,135
+$135 (+13.5%) today · 1.14× · US Dollar
Based on a EW entry price of $76.22 vs. today's $86.51.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $82.97 | $1,042.67 | +4.3% |
| 1 month ago | $83.46 | $1,036.54 | +3.7% |
| 3 months ago | $85.9 | $1,007.1 | +0.7% |
| 6 months ago | $86.67 | $998.15 | -0.2% |
| 1 year ago | $76.22 | $1,135 | +13.5% |
| All time (5.0y) ago | $95.12 | $909.48 | -9.1% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our EW forecast.
Our base-case forecast reaches $170.00 around 2032.
Implied market cap at $170.00: $97.89B
The multi-year forecast shows a bullish trajectory with rising averages and sizable upside. In 2026, the average price is projected at $85.72 with a min of $75.87 and a max of $112.40; the ROI is 0 and sentiment is NEUTRAL.
From 2027 onward, the average price climbs to $103.27 (ROI 20.5) with a min of $84.31 and a max of $132.46, continuing a bullish trend through 2035 and beyond. Notable milestones include 2030 with an average of $144.17 (ROI 68.2) and a max of $197.15, and 2040 with an average of $367.13 (ROI 328.3).
By 2050, the forecast shows an average price of $733.34 (ROI 755.5) with a max of $1,202.15 and a min of $484.24, maintaining a bullish sentiment across the horizon. These are estimates and not guarantees, and actual results may differ due to market conditions and other factors.
Tap a question to reveal the answer.
In 2030, the forecast shows a min of $112.34, an average of $144.17, and a max of $197.15, with an ROI of 68.2 and a bullish sentiment.
The forecast indicates a bullish trajectory beyond 2026, with increasing averages and ROIs including 2027 avg $103.27 (ROI 20.5), 2029 avg $121.03 (ROI 41.2), and 2050 avg $733.34 (ROI 755.5), though 2026 is neutral. These are estimates and not guarantees.
The 2030 max forecast is $197.15, which is just below $200.
The current price is $85.72 and the market cap is $49.36B.
The 30-day range is $77.27 to $95.10.
Edwards Lifesciences Corporation Community Discussion
0Share your Edwards Lifesciences Corporation price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.